ReWalk Robotics Ltd.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IL0011331076
USD
0.70
0.15 (27.27%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

2.27 M

Shareholding (Mar 2025)

FII

4.55%

Held by 9 FIIs

DII

95.16%

Held by 0 DIIs

Promoter

0.00%

How big is ReWalk Robotics Ltd.?

22-Jun-2025

As of Jun 18, ReWalk Robotics Ltd. has a market capitalization of 12.74 million, with net sales of 25.41 million and a net profit of -27.49 million over the latest four quarters. Shareholder's funds are 18.85 million, and total assets are 30.49 million.

As of Jun 18, ReWalk Robotics Ltd. has a market capitalization of 12.74 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 25.41 million, while the sum of net profit for the same period is -27.49 million.<BR><BR>As of Dec 24, the shareholder's funds amount to 18.85 million, and total assets are reported at 30.49 million.

Read More

What does ReWalk Robotics Ltd. do?

22-Jun-2025

ReWalk Robotics Ltd. designs and develops exoskeletons for individuals with mobility impairments, operating in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $5 million and a net loss of $5 million, with a market cap of $12.74 million.

Overview: <BR>ReWalk Robotics Ltd. is a medical device company engaged in designing, developing, and commercializing exoskeletons for individuals with mobility impairments, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 5 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 12.74 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.29 <BR>Return on Equity: -95.94% <BR>Price to Book: 0.69<BR><BR>Contact Details: <BR>Address: 3 Hatnufa st. 6th fl., P.O. Box 161 YOKNEAM None : 2069203 <BR>Tel: ['972 4 9590123'] <BR>Website: http://rewalk.com

Read More

Who are in the management team of ReWalk Robotics Ltd.?

22-Jun-2025

As of March 2022, the management team of ReWalk Robotics Ltd. includes Mr. Jeff Dykan (Independent Chairman), Mr. Lawrence Jasinski (CEO and Director), and Directors Mr. Aryeh Dan, Mr. Yohanan Engelhardt, Mr. Yasushi Ichiki, and Ms. Randel Richner. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of ReWalk Robotics Ltd. includes the following individuals:<BR><BR>- Mr. Jeff Dykan, Independent Chairman of the Board<BR>- Mr. Lawrence Jasinski, Chief Executive Officer and Director<BR>- Mr. Aryeh Dan, Director<BR>- Mr. Yohanan Engelhardt, Director<BR>- Mr. Yasushi Ichiki, Director<BR>- Ms. Randel Richner, Director<BR><BR>This team oversees the strategic direction and operations of the company.

Read More

Should I buy, sell or hold ReWalk Robotics Ltd.?

22-Jun-2025

Is ReWalk Robotics Ltd. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, the market trend is bearish, supported by bearish daily moving averages and Bollinger Bands, despite some mildly bullish signals from the MACD and mixed readings from the KST.

As of 9 September 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish, with key indicators supporting this view. The daily moving averages are bearish, and both the weekly and monthly Bollinger Bands are also bearish. Although the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall trend is dominated by bearish signals from the moving averages and Bollinger Bands. The Dow Theory indicates a mildly bearish stance on the monthly time frame, while the KST shows mixed signals with a mildly bullish weekly reading but bearish monthly. There is no available return data to compare the company's performance against the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROE of 0%

  • The company has reported losses. Due to this company has reported negative ROE
2

Flat results in Jun 25

3

Risky - Negative EBITDA

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 9 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.33

stock-summary
Return on Equity

-113.71%

stock-summary
Price to Book

0.58

Revenue and Profits:
Net Sales:
6 Million
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
22.7%
0%
22.7%
6 Months
-44.0%
0%
-44.0%
1 Year
-64.29%
0%
-64.29%
2 Years
-85.75%
0%
-85.75%
3 Years
-23.57%
0%
-23.57%
4 Years
-91.67%
0%
-91.67%
5 Years
-92.0%
0%
-92.0%

ReWalk Robotics Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
38.23%
EBIT Growth (5y)
-9.46%
EBIT to Interest (avg)
-17.50
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
0.66
Tax Ratio
0.17%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.46%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.76
EV to EBIT
-0.48
EV to EBITDA
-0.58
EV to Capital Employed
0.66
EV to Sales
0.34
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-136.62%
ROE (Latest)
-95.94%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 3 Schemes (0.28%)

Foreign Institutions

Held by 9 Foreign Institutions (4.55%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 14.00% vs -33.33% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -37.50% vs 68.63% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.70",
          "val2": "5.00",
          "chgp": "14.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.70",
          "val2": "-4.80",
          "chgp": "22.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.60",
          "val2": "-4.80",
          "chgp": "-37.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-660.40%",
          "val2": "-964.00%",
          "chgp": "30.36%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 84.89% vs 152.73% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -30.77% vs -12.76% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "25.70",
          "val2": "13.90",
          "chgp": "84.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.70",
          "val2": "-18.60",
          "chgp": "15.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-9.80",
          "val2": "-3.20",
          "chgp": "-206.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-28.90",
          "val2": "-22.10",
          "chgp": "-30.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-761.90%",
          "val2": "-1,475.50%",
          "chgp": "71.36%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
5.70
5.00
14.00%
Operating Profit (PBDIT) excl Other Income
-3.70
-4.80
22.92%
Interest
0.00
0.00
Exceptional Items
-2.80
0.00
Consolidate Net Profit
-6.60
-4.80
-37.50%
Operating Profit Margin (Excl OI)
-660.40%
-964.00%
30.36%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 14.00% vs -33.33% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -37.50% vs 68.63% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
25.70
13.90
84.89%
Operating Profit (PBDIT) excl Other Income
-15.70
-18.60
15.59%
Interest
0.10
0.00
Exceptional Items
-9.80
-3.20
-206.25%
Consolidate Net Profit
-28.90
-22.10
-30.77%
Operating Profit Margin (Excl OI)
-761.90%
-1,475.50%
71.36%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 84.89% vs 152.73% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -30.77% vs -12.76% in Dec 2023

stock-summaryCompany CV
About ReWalk Robotics Ltd. stock-summary
stock-summary
ReWalk Robotics Ltd.
Pharmaceuticals & Biotechnology
ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. ReWalk designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers two ReWalk products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is designed for use by paraplegia patients in the clinical rehabilitation environment, where it provides exercise and therapy.
Company Coordinates stock-summary
Company Details
3 Hatnufa st. 6th fl.,, P.O. Box 161 YOKNEAM None : 2069203
stock-summary
Tel: 972 4 9590123
stock-summary
Registrar Details